Table 2.

Pharmaceutical care issues (PCIs) and active ingredients

	Phase 1		Phase 3
	n	%	n	%	P-value
Type of PCIs
Education required	259	28.9	245	30	0.1617
Monitoring issues	216	24.1	165	20.2	0.0554
Discrepancy between dose prescribed and drug used	156	17.4	159	19.5	0.0613
Potential ineffective therapy	146	16.3	122	15	0.2055
Potential/actual compliance/adherence	128	14.3	112	13.7	0.2271
Inappropriate dose regimen	116	13	90	11	0.1252
Potential/suspected adverse drug reaction	101	11.3	122	15	0.0044
Potential drug-disease interaction	82	9.2	115	14.1	0.0002 a
Inappropriate duration of therapy	53	5.9	42	5.1	0.1674
Untreated indication for therapy	40	4.5	32	3.9	0.1739
Repeat prescription no longer required	22	2.5	23	2.8	0.144
Drug use with no indication	19	2.1	29	3.6	0.0185
Others	2	0.2	0	0	0.5007 b
Total number of patients	895		816
Active ingredients
ACE-I	114	12.7	90	11	0.1452
β-Blockers	64	7.2	68	8.3	0.0838
NSAID	261	29.2	340	41.7	<0.0001 a
Total number of patients	895		816

χ ² with Bonferroni adjustment 0.05/53 0.0009

ACE-I=angiotensin-converting-enzyme inhibitors; NSAID=non-steroidal anti-inflammatory.

^a Statistical significant difference.

^b Fisher’s exact test with Bonferroni adjustment.